| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $112,814,283 | 75 | 100 |
| Coughlin Timothy | director | 0 | $0 | 2 | $642,090 | $-642,090 |
| LYONS GARY A | director | 0 | $0 | 3 | $961,406 | $-961,406 |
| Meckler Jeffrey A | director | 0 | $0 | 2 | $1.71M | $-1.71M |
| Baynes Roy D. | director | 0 | $0 | 5 | $2.55M | $-2.55M |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | 0 | $0 | 6 | $4.19M | $-4.19M |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | 0 | $0 | 10 | $4.64M | $-4.64M |
| Inrig Jula | CHIEF MEDICAL OFFICER | 0 | $0 | 11 | $5.16M | $-5.16M |
| REED ELIZABETH E | Chief Legal Officer and GC | 0 | $0 | 12 | $7.02M | $-7.02M |
| ROTE WILLIAM E. | Chief Research Officer | 0 | $0 | 6 | $16.43M | $-16.43M |
| Heerma Peter | CHIEF COMMERCIAL OFFICER | 0 | $0 | 7 | $18.7M | $-18.7M |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | 0 | $0 | 11 | $50.82M | $-50.82M |
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce …
Over the last 12 months, insiders at Travere Therapeutics, Inc. have bought $0 and sold $112.81M worth of Travere Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Travere Therapeutics, Inc. have bought $0 and sold $25.85M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $178,500 was made by ASELAGE STEVE (Chief Executive Officer) on 2017‑06‑14.
| 2026-10-15 | Sale | Dube Eric M | CHIEF EXECUTIVE OFFICER | 243,735 0.2636% | $53.82 | $13.12M | -4.36% | |
| 2026-09-17 | Sale | Dube Eric M | CHIEF EXECUTIVE OFFICER | 108,493 0.1164% | $64.61 | $7.01M | -18.78% | |
| 2026-09-17 | Sale | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | 8,282 0.009% | $65.07 | $538,917 | -18.78% | |
| 2026-09-16 | Sale | Dube Eric M | CHIEF EXECUTIVE OFFICER | 195,841 0.2105% | $63.45 | $12.43M | -17.01% | |
| 2026-09-16 | Sale | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | 172,717 0.1856% | $63.43 | $10.96M | -17.01% | |
| 2026-09-16 | Sale | ROTE WILLIAM E. | Chief Research Officer | 112,850 0.1211% | $63.33 | $7.15M | -17.01% | |
| 2026-09-15 | Sale | Dube Eric M | CHIEF EXECUTIVE OFFICER | 95,666 0.1025% | $62.26 | $5.96M | -15.55% | |
| 2026-09-15 | Sale | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | 102,190 0.1095% | $62.26 | $6.36M | -15.55% | |
| 2026-09-15 | Sale | REED ELIZABETH E | Chief Legal Officer and GC | 37,500 0.0402% | $62.34 | $2.34M | -15.55% | |
| 2026-09-15 | Sale | Inrig Jula | EVP, Head of R&D & CMO | 44,674 0.0479% | $62.34 | $2.79M | -15.55% | |
| 2026-09-15 | Sale | ROTE WILLIAM E. | Chief Research Officer | 96,198 0.103% | $62.25 | $5.99M | -15.55% | |
| 2026-09-15 | Sale | Cline Christopher R. | CHIEF FINANCIAL OFFICER | 50,508 0.0542% | $62.34 | $3.15M | -15.55% | |
| 2026-09-15 | Sale | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | 5,375 0.0058% | $62.33 | $335,005 | -15.55% | |
| 2026-09-10 | Sale | Meckler Jeffrey A | director | 20,000 0.0214% | $67.31 | $1.35M | -20.97% | |
| 2026-09-02 | Sale | Cline Christopher R. | CHIEF FINANCIAL OFFICER | 642 0.0007% | $66.37 | $42,610 | -15.44% | |
| 2026-08-18 | Sale | LYONS GARY A | director | 5,000 0.0053% | $63.37 | $316,860 | -6.24% | |
| 2026-08-17 | Sale | LYONS GARY A | director | 5,000 0.0053% | $63.20 | $315,986 | -5.57% | |
| 2026-06-12 | Sale | Coughlin Timothy | director | 10,000 0.0103% | $50.07 | $500,747 | +10.22% | |
| 2026-06-12 | Sale | Baynes Roy D. | director | 4,500 0.0046% | $50.00 | $225,000 | +10.22% | |
| 2026-05-15 | Sale | Coughlin Timothy | director | 3,250 0.0036% | $43.49 | $141,343 | +33.08% |
| Meckler Jeffrey A | director | 91500 0.0971% | $4.52M | 3 | 3 | +66.46% |
| Shkreli Martin | 1765168 1.8726% | $87.22M | 39 | 8 | +21.5% | |
| ASELAGE STEVE | 146919 0.1559% | $7.26M | 4 | 37 | +123.45% | |
| Richardson Steven Gary | director | 129165 0.137% | $6.38M | 3 | 0 | +123.82% |
| PANOFF MARC L | Chief Financial Officer | 121100 0.1285% | $5.98M | 1 | 0 | +138.48% |
| Plotkin Horacio | Chief Medical Officer | 91767 0.0974% | $4.53M | 1 | 2 | +138.48% |
| Golding Cornelius E | director | 25000 0.0265% | $1.24M | 2 | 0 | +115.2% |
$224,662,742 | 52 | 32.03% | $5.65B | |
Travere Therapeutics, Inc. (TVTX) | $11,583,737 | 45 | 49.75% | $4.66B |
$104,428,685 | 44 | 22.55% | $3.78B | |
$477,065,869 | 34 | 82.05% | $6B | |
$151,136,640 | 31 | -1.41% | $3.95B |
| Increased Positions | 167 | +59.01% | 21M | +20.91% |
| Decreased Positions | 132 | -46.64% | 21M | -20.24% |
| New Positions | 77 | New | 7M | New |
| Sold Out Positions | 38 | Sold Out | 8M | Sold Out |
| Total Postitions | 318 | +12.37% | 102M | +0.67% |
| Janus Henderson Group Plc | $418,899.00 | 11.91% | 10.6M | +1M | +11.09% | 2025-09-30 |
| Blackrock, Inc. | $320,130.00 | 9.1% | 8.1M | -68,490 | -0.84% | 2025-09-30 |
| Armistice Capital, Llc | $265,732.00 | 7.56% | 6.72M | -2M | -24.25% | 2025-09-30 |
| Vanguard Group Inc | $261,360.00 | 7.43% | 6.61M | +619,085 | +10.33% | 2025-09-30 |
| Macquarie Group Ltd | $196,981.00 | 5.6% | 4.98M | -113,149 | -2.22% | 2025-09-30 |
| Perceptive Advisors Llc | $149,963.00 | 4.26% | 3.79M | +3M | +354.85% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $140,375.00 | 3.99% | 3.55M | +768,000 | +27.59% | 2025-09-30 |
| State Street Corp | $127,169.00 | 3.62% | 3.22M | -265,337 | -7.62% | 2025-09-30 |
| Fmr Llc | $114,377.00 | 3.25% | 2.89M | +2M | +171.04% | 2025-09-30 |
| Rock Springs Capital Management Lp | $85,552.00 | 2.43% | 2.16M | +256,565 | +13.45% | 2025-09-30 |